FindTrial
Sign In

Treatment with Risedronate for dilated cardiomyopathy due to Troponin T alteration due to K210 deletion.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509431-29-00
Acronym
IMIB-TRISMD-2023-02
Enrollment
5
Registered
2024-08-26
Start date
2025-04-08
Completion date
Unknown
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy

Brief summary

Change in LVEF, measured by echocardiography, at 6 months.

Detailed description

Improvement in functional capacity, measured in the stress test with oxygen consumption, at 6 months.

Interventions

DRUGActonel 5 mg comprimidos recubiertos con película

Sponsors

Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in LVEF, measured by echocardiography, at 6 months.—

Secondary

MeasureTime frame
Improvement in functional capacity, measured in the stress test with oxygen consumption, at 6 months.—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026